Becton, Dickinson and Company (BDX) have provided a mixed bag of financial updates. The company's PT has been lowered to $270.00. Their Q3 2024 earnings were released where they beat estimates and displayed an earnings snapshot for fiscal Q3. However, their stock shares dipped to $241.06 causing some investors such as Burney Co. and Madison Investors Fund to reduce their holdings. However, some believe that BDX is a strong buy stock. Lazard Asset Management LLC and Lbp Am Sa purchased shares while Swedbank AB acquired over 144,000 more. Their Q3 earnings surpassed estimates and saw expanding margins. However, their stock has slipped due to financial outlook concerns and was downgraded to “Hold”. The fiscal 2024 earnings guidance was released with sustained product demand expected to aid Q3 earnings. Despite the lower-than-expected 2024 guidance, the company exceeded Q2 earnings estimates and raised its fiscal 2024 guidance. A notable event was the purchase of Edwards Lifesciences' critical care product group for $4.2B in cash. Allen Sseau, an analyst, remains optimistic about the company's potential to achieve its 2025 commitments.
Becton Dickinson and BDX News Analytics from Thu, 09 Nov 2023 08:00:00 GMT to Sun, 04 Aug 2024 17:24:17 GMT -
Rating 3
- Innovation -1
- Information 7
- Rumor -5
